CAR T cells targeting IL-13Rα2 and EGFRvIII have had limited responses in GBM due to the heterogenous nature of GBM and multiple immunosuppressive mechanisms present in the tumor microenvironment [30]. The gene discussed is IL13RA2; the disease is glioblastoma.